Pyrazino isoquinolines

Praziquantel (Fig. 4.9), a racemate derivative of pyrazino-isoquinoline, is effective against many species of cestodes and trematodes. It is indicated for use in nonlactating sheep in form of a single oral dose of 3.75 mg/kg bw. 

Included in the class of macrocyclic lactones are avermectins and milbemycins, which are fermentation products possessing a 16-member cyclic lactone, a spiroketal moiety, and a disaccharide unit. Abamycin, ivermectin, doramectin, and eprinomycin are the avermectins most often available for anthelminthic treatment of livestock, whereas moxidectin is a milbemycin with worldwide acclaim as a cattle anthelminthic. Other anthelminthics currently used in food-producing animals are clorsulon, which is a benzenesulphonamide derivative praziquantel, which is a racemate derivative of pyrazino-isoquinoline and hygromycin B, which is an aminoglycoside antibiotic that exhibits anthelminthic properties. 

Pra.ziciua.nteL This drug (1), C19H24N202, can be used to treat schistosomiasis caused by any one of the three major species. Praziquantel is an acylated pyrazino—isoquinoline derivative that has replaced the traditional (and more toxic) trivalent antimonial compounds. 

The one report of a true [3-1-3] cyclization occurs in the only reported synthesis of the pyrazino[2,3-c]isoquinoline ring system. The isoquinolino fused derivative (451) was isolated from dimerization of an intermediate iminoquinone formed by air oxidation of the unstable 4-amino-2-methyltetrahydroisoquinolin-l-one (450) 75JOC1760). 

A related substance of quinapril, 3-methyl-a-(2-phenylethyl)-l,4-dioxo-1,3,4,6,11,1 lfl-hexahydro-2//-pyrazino[l,2-A]isoquinoline-2-acetic acid, was determined by a HPLC method in drug substance (00MI55). 

Structure of 4//-pyrido[l,2-a]pyrazines 348-350 was confirmed by X-ray investigations (99JPR332). The stereostructure of 1,3,4,6,1 l,lla-hexahydro-2/f-pyrazino[l,2-A]isoquinoline-l,4-dione 351 was determined by X-ray investigation (01TL543). 

Reduction of a 7-(2-oxoethyl) derivative with NaBH4 in EtOH at room temperature gave 7-(2-hydroxyethyl)-2-(2-pyrimidinyl)perhydropyrido[l, 2-u]pyrazine (99MIP6). Reduction of 7-formyl-8-[(4-cyanophenyl)methoxy]-1,3,4,6,11,1 lu-hexahydro-2//-pyrazino[l,2-A]isoquinoline-l,4-dione with NaBH4 yielded a 7-hydroxymethyl derivative (98MIP7). 

The side chain C=C double bond of 2,3,4,6,ll,lln-hexahydro-l//-pyrazino[l,2-i]isoquinoline-l,4-diones 354 was saturated by catalytic hydrogenation over Pd/C catalysts in EtOH to give 355 (98MIP7). 7-(2-Pyridylmethyl)amino derivative was obtained by reduction of 7-[(2-pyridylmethylene)amino]-2,3,11,11 n-tetrahydro-6//-pyrazino[l, 2-i]isoqui-noline-l,4-dione (356) with NaBH4 in EtOH at ambient temperature for 24 h. 

Vilsmeier formylation of praziquantel (9) with DMF-POCI3 at 60 °C for 5 h gave 2-cyclohexylcarbonyl-3-dimethyliminiummethylene-4-chloro-1,6,7,116-tetrahydro-2//-pyrazino[2,l-u]isoquinoline salt (01PHA146). 

Hydroxy group of 8-hyd oxy-2-cycloalkyl-2,3,4,6,ll,lla-hexahydro-l//-pyrazino[l,2-i]isoquinoline-l,4-diones was alkylated with allyl bromide, 2-(bromodifluoromethyl)pyridines, l-(bromodifluoromethyl)- and l-(bro-momethyl)benzenes, halomethyl derivatives of different heterocycles (pyridine, pyrazine, pyrazole, pyrrole, thiazole, thiophene) in the presence of CS2CO3 or K2CO3 (98MIP7). Hydroxy group of 8-hydroxy-2-cyclopentyl-... 

Aminothiocarbonylphenyl)methoxy] derivative 384 was obtained from 8-[(4-cyanophenyl)methoxy]-2-cyclohexy 1-2,3,4,6,11,11 a-hexahydro-l/7-pyrazino[l,2-i]isoquinoline-l,4-dione by treatment with (EtO)2P(S)SH and one drop of H2O at room temperature for 17 h, then followed by addition of more H2O (98MIP7). Reaction of 8-[(4-aminothiocarbonylphe-nyl)methoxy] derivative 384 and MeCOCH2Cl yielded 8- [4-(4-methylthia-zol-2-yl)phenyl]methoxy derivative 385. 7-Bromomethyl derivative was prepared from the 8-hydroxymethyl-8-[(4-cyanophenyl)methoxy]-2-cyclo-pentyl-2,3,4,6,11,1 la-hexahydro-177-pyrazino[l, 2-i]isoquinoline-1,4-dione with PBr3 in CH2CI2 at room temperature. 7-[(l-Pyrazolyl)methyl] derivative was obtained from 7-bromomethyl derivative by treatment with pyrazole in the presence of NaH in DMF at 50 °C. 

Treatment of 8-[(4-cyanophenyl)methoxy]-7-formyl-2-cyclopentyl-2,3,4,6,11,1 la-hexahydro-l//-pyrazino[l,2-i]isoquinoline-l,4-dione with (Et0)2P(0)CH2C00Et and NaH in THF at 40 °C overnight, or with (2-pyridylmethyl)-, 4-[(ethoxycarbonyl)benzyl]-, (4-nitrobenzyl)-, and (meth-oxymethyl)triphenylphosphonium halogenide in the presence of KH in THF at room temperature gave 7-ethylene derivatives 386 (98MIP7). 

Cyclocondensation of 2-(2-chloroacetyl)-l, 2,3,4-tetrahydroisoquinoline-3-carboxylate 418 (R =N02, R = Me) with liquid NH3 in MeOH in a stainless steel pressure vessel at room temperature overnight gave 8-nitro-2,3,4,6,1 1,1 la-hexahydro-l//-pyrazino[l,2-i]isoquinoline-l,4-dione (419, R=H, R =N02) (97MIP4). (1 la/i)-2-Cycloalkyl-8-hydroxy-2,3,4,6,ll, 1 la-hexahydro-l//-pyrazino[l,2-i]isoquinoline-l,4-diones 419 (R = cycloalkyl, R = OH) were prepared in the reactions of (3/i)-2-chloroace-tyl-l,2,3,4-tetrahydroisoquinoline-3-carboxylate (418, R = OH, R = Et) with cycloalkylamines (98MIP7). 

Treatment of tetracyclic nitrogen bridgehead compound 433 with NaCN resulted the formation of 4-cyano derivative of 1,2,3,4,1 lu-hexahydro-6//-pyrazino[l, 2-h]isoquinoline 434 (00BMC523). 

Inhibition of human multidrug resistance P-glycoprotein 1 was investigated by analogs of a potent. 5-opioid antagonist, including (35, 1 lu5)-3-[(4-hydroxy-2,6-dimethylphenyl)methyl]-11,11 u-dihydro-2//-pyrazino[l, 1-b] isoquinoline-l,4(3//,6//)-dione (OIMIIO). Opioid antagonist activity of... 

Cyclomethycaine Oxyphencyclimine Tridihexethyl iodide Trihexyphenidyl HCl 2-Cyclohexylcarbonyl-4-oxo-2,3,6,7-tetrahydro-4H-pyrazino[2,1 -a] isoquinoline Praziquantel... 

---